CN112752837A - 天然杀伤细胞 - Google Patents

天然杀伤细胞 Download PDF

Info

Publication number
CN112752837A
CN112752837A CN201980050463.XA CN201980050463A CN112752837A CN 112752837 A CN112752837 A CN 112752837A CN 201980050463 A CN201980050463 A CN 201980050463A CN 112752837 A CN112752837 A CN 112752837A
Authority
CN
China
Prior art keywords
cells
compound
rev
erb
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980050463.XA
Other languages
English (en)
Chinese (zh)
Inventor
马修·富希特
阿米娅·乌里兹·瓦尔特
休·J·M·布雷迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imperial Institute Of Technology Innovation Co ltd
Original Assignee
Imperial Institute Of Technology Innovation Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Institute Of Technology Innovation Co ltd filed Critical Imperial Institute Of Technology Innovation Co ltd
Publication of CN112752837A publication Critical patent/CN112752837A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201980050463.XA 2018-06-26 2019-06-26 天然杀伤细胞 Pending CN112752837A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1810486.9 2018-06-26
GBGB1810486.9A GB201810486D0 (en) 2018-06-26 2018-06-26 Natural killer cells
PCT/GB2019/051803 WO2020002911A1 (en) 2018-06-26 2019-06-26 Natural killer cells

Publications (1)

Publication Number Publication Date
CN112752837A true CN112752837A (zh) 2021-05-04

Family

ID=63042803

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980050463.XA Pending CN112752837A (zh) 2018-06-26 2019-06-26 天然杀伤细胞

Country Status (8)

Country Link
US (1) US12377119B2 (https=)
EP (1) EP3814485A1 (https=)
JP (2) JP7527207B2 (https=)
CN (1) CN112752837A (https=)
AU (1) AU2019293163B2 (https=)
CA (1) CA3104674A1 (https=)
GB (1) GB201810486D0 (https=)
WO (1) WO2020002911A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201703476D0 (en) 2017-03-03 2017-04-19 Imp Innovations Ltd Natural killer cells
GB201810486D0 (en) * 2018-06-26 2018-08-08 Imperial Innovations Ltd Natural killer cells
AU2021372389A1 (en) * 2020-10-16 2023-05-11 Pelagos Pharmaceuticals, Inc. Rev-erb agonists
WO2024047368A1 (en) 2022-09-02 2024-03-07 Imperial College Innovations Limited Natural killer cells
GB202217507D0 (en) 2022-11-23 2023-01-04 Imperial College Innovations Ltd Natural killer cells
AU2024212529A1 (en) * 2023-01-27 2025-06-19 Opna Bio SA Compounds and methods for yap/tead modulation and indications therefor

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050020645A1 (en) * 2001-06-20 2005-01-27 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
CN102781449A (zh) * 2009-12-29 2012-11-14 加米达细胞有限公司 增强自然杀伤细胞增殖和活性的方法
WO2013033310A1 (en) * 2011-08-31 2013-03-07 Theodore Mark Kamenecka Modulators of rev-erb
US20140072545A1 (en) * 2010-12-03 2014-03-13 Regents Of The University Of Minnesota Generation of natural killer cells and lymphoid tissue inducer-like (lti-like) nk-22 cells
CN103710304A (zh) * 2012-09-29 2014-04-09 北京东方百奥医药开发有限公司 脂肪干细胞诱导分化为自然杀伤细胞的方法及用途
US20160237057A1 (en) * 2013-10-09 2016-08-18 Fondazione Istituto Italiano Di Tecnologia Diarylalkylamine rev-erb antagonists and their use as medicaments

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59141562A (ja) * 1983-02-01 1984-08-14 Nippon Kayaku Co Ltd Ｎ，ｎ′−置換イミダゾ−ルカルボキサミド誘導体および農園芸用殺菌殺線虫剤
JPS60109568A (ja) * 1983-11-17 1985-06-15 Ube Ind Ltd イミダゾ−ル誘導体および農園芸用殺菌剤
GB9206757D0 (en) * 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
AU5845096A (en) * 1995-05-31 1996-12-18 Nissan Chemical Industries Ltd. 5-pyrazolecarboxamide derivatives and plant disease control agent
EP1001764A4 (en) * 1997-05-29 2005-08-24 Merck & Co Inc HETEROCYCLIC AMIDE COMPOUNDS AS INHIBITORS OF CELL ADHESION
WO2000046204A1 (en) 1999-02-04 2000-08-10 Sk Corporation Tetrahydro isoquino linealkanol derivatives and pharmaceutical compositions containing same
EP1442028A4 (en) * 2001-11-06 2009-11-04 Bristol Myers Squibb Co SUBSTITUTED ACID DERIVATIVES, WHICH APPRECIATE AS ANTIDIBILICS AND AGENTS AGAINST OBESITAS, AND METHODS
BR0312503A (pt) * 2002-07-09 2007-06-26 Bristol Myers Squibb Co derivados heterocìclicos substituìdos úteis como agentes antidiabéticos e antiobesidade, composição farmacêutica, uso e combinação dos mesmos
US20090062212A1 (en) 2007-05-07 2009-03-05 Elliott Richelson Peptide analogs that are potent and selective for human neurotensin preceptor subtype 2
CA3080368A1 (en) * 2009-12-04 2011-06-09 Stem Cell & Regenerative Medicine International, Inc. Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts
WO2012128622A1 (en) 2011-03-18 2012-09-27 Ipd-Therapeutics B.V. Generation of nk cells and nk-cell progenitors
US9175266B2 (en) * 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
WO2015103527A1 (en) 2014-01-06 2015-07-09 The Scripps Research Institute Modulators of rev-erb
GB201703476D0 (en) * 2017-03-03 2017-04-19 Imp Innovations Ltd Natural killer cells
GB201704953D0 (en) * 2017-03-28 2017-05-10 Imp Innovations Ltd Natural killer cells
WO2018178663A1 (en) * 2017-03-30 2018-10-04 Parker Hannifin Manufacturing Limited A pressure swing adsorption system with a variable flow restrictor
GB201810486D0 (en) * 2018-06-26 2018-08-08 Imperial Innovations Ltd Natural killer cells

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050020645A1 (en) * 2001-06-20 2005-01-27 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
CN102781449A (zh) * 2009-12-29 2012-11-14 加米达细胞有限公司 增强自然杀伤细胞增殖和活性的方法
US20140072545A1 (en) * 2010-12-03 2014-03-13 Regents Of The University Of Minnesota Generation of natural killer cells and lymphoid tissue inducer-like (lti-like) nk-22 cells
WO2013033310A1 (en) * 2011-08-31 2013-03-07 Theodore Mark Kamenecka Modulators of rev-erb
CN103710304A (zh) * 2012-09-29 2014-04-09 北京东方百奥医药开发有限公司 脂肪干细胞诱导分化为自然杀伤细胞的方法及用途
US20160237057A1 (en) * 2013-10-09 2016-08-18 Fondazione Istituto Italiano Di Tecnologia Diarylalkylamine rev-erb antagonists and their use as medicaments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
王学富;田志刚;: "NK细胞发育分化分子机制及其相关疾病研究进展", 中国免疫学杂志, no. 05 *

Also Published As

Publication number Publication date
JP2021528969A (ja) 2021-10-28
US20220073880A1 (en) 2022-03-10
AU2019293163B2 (en) 2025-10-23
CA3104674A1 (en) 2020-01-02
WO2020002911A1 (en) 2020-01-02
AU2019293163A1 (en) 2021-01-21
JP2024095819A (ja) 2024-07-10
JP7527207B2 (ja) 2024-08-02
EP3814485A1 (en) 2021-05-05
GB201810486D0 (en) 2018-08-08
US12377119B2 (en) 2025-08-05

Similar Documents

Publication Publication Date Title
CN112752837A (zh) 天然杀伤细胞
US20230002467A1 (en) Superagonists, partial agonists and antagonists of interleukin-2
KR100458403B1 (ko) 생체외 조혈세포의 자극방법
CA2334155C (en) Cyclic boroproline compounds
JP2022532247A (ja) Ｃｂｌ－ｂ阻害のためのシアノシクロブチル化合物及びその使用
JP2022549007A (ja) 養子細胞療法に使用するためのｃｂｌ阻害剤および組成物
EA025215B1 (ru) Новые антитела к cd38 для лечения рака
BR112019022356A2 (pt) Reagentes de partícula oligoméricos e métodos de uso dos mesmos
EP4301755A1 (en) Combination of a t cell therapy and a dgk inhibitor
CN109348714A (zh) 吲哚胺2,3-双加氧酶的抑制剂及其使用方法
JP2019513836A (ja) 二重特異性抗体を使用して患者の造血幹細胞／造血前駆細胞（ｈｓｃ／ｈｐ）を除去する方法
CN110709507A (zh) 自然杀伤细胞
JP2001511649A (ja) サイトカインレセプターガンマ鎖のペプチド模倣物
CN114901684A (zh) 粒细胞集落刺激因子受体(g-csfr)的经修饰胞外结构域和结合其的细胞因子
CN120518771A (zh) 一种识别kras突变的t细胞受体及其编码序列
JP2002281963A (ja) 組換え熱ショックタンパク質７０による樹状細胞の成熟
Cui et al. CD30 plays a role in T‐dependent immune response and T cell proliferation
JPH07502165A (ja) Ｔリンパ球の限定された個体群に対する抗体を生産する方法、抗体および使用方法
SA109300384B1 (ar) مشتقات 5-(4- ميثان سلفونيل-فينيل)- ثيازول لعلاج الأمراض الالتهابية الحادة والمزمنة
JP6818099B2 (ja) デスリガンドへの移植前曝露による造血前駆細胞の活性化
KR20260028777A (ko) 항암제로서의 치환된 옥소이소인돌리닐 피페리딘-2,6-디온 화합물
TWI354664B (en) Cyclic derivatives as modulators of chemokine rece
WO2024037322A1 (zh) 一种IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途
CN120693400A (zh) 自然杀伤细胞
CN120152717A (zh) T细胞疗法和连续或间歇dgk抑制剂给药的组合

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination